RFK Jr Moves to Loosen Rules on Six Unapproved Peptides
US Health Secretary Robert F Kennedy Jr. has advanced plans to widen access to six controversial peptides by allowing compounding pharmacies to prepare them, despite the fact that they are not approved by the Food and Drug Administration. The proposal was published in the US Federal Register and will enter a two-week public comment period after formal publication later this week. In a notable procedural shift, the draft emerged from the office of the health secretary rather than the FDA itself.
The peptides named in the plan are BPC-157, TB-500, KPV, MOTS-c and Semax, along with a sixth peptide covered by the same change. If implemented, compounding pharmacies would be able to mix these substances into medications for patients, even though the compounds have not gone through the standard FDA approval pathway for safety and efficacy in humans. Kennedy has publicly described himself as a “big fan” of the drugs and has said he wants to ease restrictions after the Biden administration tightened oversight.
Unapproved injectables have already gained traction in online wellness circles, where marketing often outruns evidence.
A Regulatory Shift With Limited Human Data Behind It
Peptides are short chains of amino acids, and many occur naturally in the body as signaling molecules. They influence cellular behavior across skin, immune function, and hormone regulation, which is why the class has long been medically relevant. Insulin is the most familiar example: one of the first peptide hormones identified, it remains essential for people with Type 1 diabetes and for many with Type 2 diabetes who need blood sugar control.
The compounds now under scrutiny sit in a very different category. They have been promoted online for unproven uses, including skin rejuvenation, accelerated healing, and muscle building. Influencers frequently market them in “stacks,” a term used to suggest that combinations of peptides can deliver broader benefits than any single product. The public-facing claims are broad, but the clinical evidence base for those claims remains thin, especially for long-term use in humans.
That gap matters because biologic activity does not equal clinical safety. A molecule can alter signaling pathways and still carry unknown risks when used repeatedly, injected outside a trial setting, or combined with other agents sold for wellness purposes. The absence of robust human trial data leaves unresolved questions about dose, contamination, systemic effects, and whether any purported benefit survives controlled testing.
FDA Staff Had Recommended Against Easing Restrictions
The proposal also exposes tension inside the federal process. An FDA advisory panel voted in July to loosen restrictions on the six peptides, but FDA staff members recommended against doing so. Those competing positions point to a familiar regulatory dilemma: how to handle compounds with growing public demand but incomplete evidence. The agency’s standard framework favors documented safety and efficacy before broad market access, while compounding allows customized preparation in narrower circumstances.
Kennedy’s intervention shifts the center of gravity toward broader availability. By channeling the draft through his office, the administration is signaling a willingness to challenge the FDA’s more cautious posture. For clinicians, pharmacists, and patients, the practical result could be a faster path to access, but not one necessarily backed by the kind of data that normally supports routine prescribing.
The timing is especially consequential because the compounds are already circulating in an aggressive online marketplace. Once a product enters that ecosystem, claims can spread faster than evidence, and users may assume that availability equals validation. It does not.
Online Demand Has Outpaced the Science
The popularity of peptides has expanded in the shadow of GLP-1 weight loss drugs, which brought peptide-based therapy into the mainstream conversation. That mainstreaming has spilled into broader wellness culture, where unregulated peptides are being sold as tools for looking younger, recovering faster, or improving physical appearance. Some of the most active promotion has targeted teenagers on TikTok, especially boys, through trends labeled “biohacking” and “looksmaxxing.”
For adolescents, the concern is more than hype. Young users may be especially vulnerable to persuasive claims about muscle gain or physique enhancement, while lacking the clinical literacy to distinguish approved medicines from compounds sold for speculative benefit. Injectable products obtained outside regulated channels also raise concerns about product quality, labeling accuracy, and sterile preparation. Those risks become more serious when compounds are mixed by compounding pharmacies for uses that have not been established in controlled trials.
Health experts have warned repeatedly that the long-term effects remain unknown. The biologic promise of peptides has encouraged experimentation, but the evidence needed to separate plausible mechanism from actual patient benefit has not kept pace. Without human trials that define indications, adverse effects, pharmacokinetics, and durable outcomes, the market is driven largely by expectation.
Compounding Access Could Normalize a Weak Evidence Base
Allowing compounding pharmacies to prepare these peptides could broaden access quickly, but it may also normalize use before the medical system has established a clear role for them. Compounded products often fill gaps left by commercial manufacturing, yet they are not interchangeable with FDA-approved therapies. When compounds are used outside approved pathways, clinicians lose some of the protections that come with standardized manufacturing, labeling, and premarket review.
The stakes are not abstract. Injectables carry their own burden of risk, and the promise of “natural” or body-derived signaling molecules can obscure the need for rigorous oversight. If these peptides move further into routine availability, prescribers will face pressure to answer practical questions the evidence cannot yet resolve: who should receive them, at what dose, for how long, and with what monitoring.
The proposed change is now set for public comment, and the FDA has not yet issued a formal response in this round. For the moment, the policy debate rests on a stark imbalance: rising consumer demand on one side, and an unproven clinical record on the other. The compounds may be familiar in wellness marketing, but familiarity is not the same as medical validation.